Generex Biotechnology Announces New Structure, Pay

Generex Biotechnology Announces New Structure, Pay Date and Ex-Date
for the Previously Postponed Shareholder Stock Dividend and Declares a
New Share Dividend in NuGenerex Immuno-Oncology
- Generex will give a 2 to 5 stock dividend to shareholders paying 2 GNBT
shares for every 5 shares held
- Shareholders to receive an additional 2 to 5 stock dividend of NuGenerex
Immuno-Oncology shares
- New Dates Established for shareholder stock dividend
o New Pay Date: January 3, 2020
o New Ex-Date: January 6, 2020
o Record Date remains August 30, 2019
MIRAMAR, FL, December 10, 2019/ -- Generex Biotechnology Corporation
(www.generex.com) (OTCQB:GNBT) (“Generex”) today announced revisions to the
previously announced share dividend. Generex will now pay the postponed 1:1 dividend
at a ratio of 2 to 5; i.e. for every 5 shares of Generex you own on the pay date you get 2
new Generex shares. The new pay date for this 2:5 dividend will be January 3, 2020 with
an ex-date of January 6, 2020. Please remember if you sell your shares before the ex-date
you will get a pay due bill and your dividend shares will go to the buyer. Conversely, if
you buy shares up through the ex-date, you will receive the dividend through the “Pay
Due” system and the seller will automatically pay you the dividends through broker to
broker transfer.
As part of the dividend restructuring, Generex will also pay a new stock dividend of 2 to
5 in NuGenerex Immuno-Oncology shares; i.e. for every 5 shares of Generex Stock you
own you will receive two shares of NuGenerex Immuno-Oncology (NGIO). This dividend
will also be paid on January 3, 2020 with the ex-date of January 6, 2020. NGIO, a
majority owned subsidiary of Generex, is being spun out of the parent company to form
a new, publicly traded oncology company focused on modulation of the immune system
to treat cancer. Generex management is in the process of filing the requisite legal
documents, conducting the necessary 2-year audits, preparing the S1 filing, and
planning to initiate operations as a new public company.
Joe Moscato, President & CEO of Generex said, “I am happy that we have gotten back
on track with our postponed share dividend. It has always been a part of the Generex
plan to build value for investors and to share our successes with our shareholders. We
Page 2 of 3
are still working to legally undo the harm caused by the improper trading that led to the
postponement of the dividend, and with this revised dividend structure, we believe we
have found a way to reward our loyal shareholders while we do everything necessary to
hold liable those parties who have committed improprieties. The good thing is, we can
now give a sizable dividend in our soon to be public cancer company, NGIO, which will
provide our shareholders with additional value. Please remember, our first major 20:1
dividend was postponed two times last year but was still highly successful in building
shareholder value. Many thanks to all of our shareholders for your patience. We see no
other problems in paying the restructured dividend on the new pay date of January 6,
2020, and we look forward to paying both dividends in the new year. We are excited for
Generex in the new decade as we integrate our new subsidiaries and activate our
operations with a mission to build a large integrated healthcare enterprise.”